| Literature DB >> 35077681 |
Amanda Jack1, Yoonji Kim2, Amy R Strom3, Daniel S W Lee4, Byron Williams5, Jeffrey M Schaub6, Elizabeth H Kellogg5, Ilya J Finkelstein7, Luke S Ferro8, Ahmet Yildiz9, Clifford P Brangwynne10.
Abstract
Telomeres form unique nuclear compartments that prevent degradation and fusion of chromosome ends by recruiting shelterin proteins and regulating access of DNA damage repair factors. To understand how these dynamic components protect chromosome ends, we combine in vivo biophysical interrogation and in vitro reconstitution of human shelterin. We show that shelterin components form multicomponent liquid condensates with selective biomolecular partitioning on telomeric DNA. Tethering and anomalous diffusion prevent multiple telomeres from coalescing into a single condensate in mammalian cells. However, telomeres coalesce when brought into contact via an optogenetic approach. TRF1 and TRF2 subunits of shelterin drive phase separation, and their N-terminal domains specify interactions with telomeric DNA in vitro. Telomeric condensates selectively recruit telomere-associated factors and regulate access of DNA damage repair factors. We propose that shelterin mediates phase separation of telomeric chromatin, which underlies the dynamic yet persistent nature of the end-protection mechanism.Entities:
Keywords: DNA repair; chromatin organization; phase separation; shelterin; telomeres
Mesh:
Substances:
Year: 2022 PMID: 35077681 PMCID: PMC8988007 DOI: 10.1016/j.devcel.2021.12.017
Source DB: PubMed Journal: Dev Cell ISSN: 1534-5807 Impact factor: 12.270
Figure 1.Telomeres in living cells exhibit liquid-like behavior.
A. (Top) FRAP of miRFP-TRF1 at a telomere in a U2OS cell. (Bottom) Recovery of mGFP-TRF2 or miRFP-TRF1 fluorescence at telomeres in U2OS cells (±SD, n = 9 and 11 telomeres respectively). B. (Inset) Trajectories of individual telomeres are colored separately by trajectory duration in a HeLa cell expressing GFP-TRF1. MSD analysis of these trajectories revealed subdiffusive motion with exponent α = 0.54 ± 0.01 and diffusion coefficient D = 2.8 ± 0.1 × 10−3 μm2 s−α (±SE). The slope of the dashed line serves as a reference for α = 0.5. C. Schematic of the optogenetically-induced telomere coalescence experiment: FUSN-miRFP-TRF1 serves as a seed at telomeres to recruit FUSN Corelet droplets upon local light activation. After two of these droplets merge, light is deactivated to pull telomeres together as the FUSN droplet shrinks. D. Pre-activation, activation, and deactivation of FUSN-miRFP-TRF1 and FUSN Corelets in U2OS cells. The ellipse in the schematic merged images shows the local activation pattern. E. Kymograph shows that the two telomeres coalesce and remain as a single spot after deactivation. White arrowheads indicate the merging of FUSN Corelet droplets and telomeres. F. XY and XZ views of the telomeres before and after activation. White arrowheads mark two telomeres that merge. G. The average intensities of the two telomeres add up (dashed lines) as they coalesce (black arrowhead) into a single spot. See also Figure S1 and Movie S1-3.
Figure 2:Telomeric DNA acts as an oligomerizing scaffold to promote TRF1 and TRF2-mediated condensation.
A. Example images of Cy3-TRF2 in the presence and absence of 8ds3ss telomeric DNA. B. The total volume of TRF2 condensates settled per micron squared area on the coverslip in the presence or absence of 2.5 μM 8ds3ss (mean ± SD, n = 30 with three technical replicates). Linear fit (solid line) reveals csat (± SE). C. The minimum TRF2 concentration that exhibits phase separation with a variable number of dsTEL repeats per DNA substrate. The total concentration of dsTEL tracts was fixed to 20 μM. D. TRF2 has a reentrant phase behavior as a function of 8ds3ss concentration. E. The total volume of TRF1 or TRF2 condensates settled per micron squared area on the coverslip under variable 8ds3ss concentration (mean ± SD, n = 20 with two technical replicates). F. Example images of Cy3-TRF1 in the presence and absence of 8ds3ss. G. The total volume of TRF1 condensates settled per micron squared area on the coverslip in the presence or absence of 2.5 μM 8ds3ss (mean ± SD, n = 30 with three technical replicates). Linear fits (solid lines) reveal csat (± SE). H. An increase in 8ds3ss concentration inhibits TRF1 phase separation. I. Fusion of TRF2 (22 μM, left) and TRF1 (44 μM, right) droplets formed in the presence of 2.5 μM 8ds3ss. J. U2OS expressing sspB-mCherry-TRF2. TRF corelets were locally activated at a single telomere (solid circle) or away from any telomere (dotted circle). K. (Top) Example images show first and last frames of locally activated TRF1, TRF1A75P, and TRF2 at telomeres (left; n = 3, 11, 10 cells analyzed, respectively) and away from telomeres (right; n = 3, 3, 4 cells analyzed, respectively) in U2OS cells. (Bottom) Quantification of change in intensity upon local activation, at and away from existing telomeres for WT TRF1, TRF1A75P, and WT TRF2. The intensity of each locally activated telomere or region was normalized to the average intensity of all other telomeres within the same activated cell. P-values were quantified by one-way ANOVA with multiple comparisons. See also Figures S2 and S3, Table S1, and Movie S4.
Figure 3.Differential drivers of TRF1 and TRF2 phase separation.
A. Domain organization and condensate state of full-length, truncated, and engineered TRF1 and TRF2 constructs in the presence and absence of 2.5 μM 8ds3ss (pI: isoelectric point). B. Brightfield images taken in the presence of 2.5 μM 8ds3ss DNA show that TRF1ΔA, TRF1Basic, and TRF2ΔB form condensates, whereas TRF2Acidic does not form condensates. C. TRF1Basic phase separation exhibits reentrant response to 0 - 250 μM 8ds3ss, whereas TRF2Acidic does not phase separate in any conditions (protein concentration was set to 20.1 μM). See also Figure S3.
Figure 4.The shelterin complex phase separates in vitro.
A. A schematic of the human shelterin complex. TRF1 and TRF2 are homodimers that bind to dsTEL, and POT1/TPP1 binds to ssTEL. TIN2 interconnects TRF1, TRF2, and TPP1, and RAP1 binds to TRF2. B-C. UV absorbance (B) and denaturing gel (C) show that 4comp1 elutes as a single complex from a gel filtration column. D. 4comp2 and 5comp exhibit reentrant responses to increasing DNA concentration similar to TRF2 droplets, while 4comp1 is inhibited by increasing DNA concentration similar to TRF1 droplets. E. The total volume of shelterin droplets settled per micron squared area on the coverslip under variable 8ds3ss concentration (mean ± SD, n = 20 with two technical replicates). F. In the presence of 2.5 μM 8ds3ss, 5comp droplets do not fuse on relevant time scales, whereas the addition of excess TRF1 or TRF2 reduces the fusion time. G. Cumulative probability of 5comp droplet fusion in the presence and absence of excess TRF1 or TRF2 after forming a contact at t = 0 s (n = 7, 4, 13, 16, 15 and 7 events from top to bottom). See also Figure S4 and Movie S4.
Figure 5.Telomeric condensates exhibit quantitative signatures consistent with multicomponent phase-separated liquids both in vitro and in living cells.
A. Example images show phase separation of 4comp1, 4comp2, and 5comp assembled using N-terminal swap or truncation mutants of TRF1 and TRF2. B. The total volume of shelterin droplets assembled with native or mutant TRF1 and TRF2 settled per micron squared area on the coverslip under different 8ds3ss concentrations (mean ± SD, n = 20 with two technical replicates). C. 53BP1 staining (magenta) of hTERT-RPE1 cells that are treated or untreated with TRF2 siRNA. Telomeres are stained with a telomeric DNA FISH probe (green). Nuclei are labeled with DAPI (blue). D. The percentage of hTERT-RPE1 cells with more than 10 53BP1 foci per nucleus under knockdown and rescue conditions. Error bars represent SEM of five biological replicates for all conditions except for TRF2ΔB and sspB-mCherry (four replicates). n > 1000 cells analyzed for all conditions. P-values were calculated by one-way ANOVA with multiple comparisons. E. Overexpression of miRFP-TRF2 leads to an increased dilute phase (nucleoplasmic) partitioning in U2OS cells. F. The dilute phase intensity increases nonlinearly as a function of the total intensity of the miRFP-TRF2 signal in U2OS cells. The data fit to a nonlinear heterotypically stabilized model (black solid curve) but not to homotypic interactions (red dashed curve). The ‘homotypic’ curve is not a flat line due to the presence of endogenous protein (see Riback et al., 2020). See also Figure S5.
Figure 6.Telomere-associated proteins modulate phase separation of shelterin droplets.
A. (Left) Increasing the molar ratio of RAP1 inhibits phase separation of TRF2 droplets. Droplets were formed in the presence of 2.5 μM 8ds3ss DNA. (Right) The total volume of TRF2 condensates settled per micron squared area on the coverslip as a function of RAP1 concentration (mean ± SD, n = 20 with two technical replicates). B. (Left) 5comp droplets formed with or without equimolar RAP1 and in the presence or absence of 2.5 μM 8ds3ss DNA. Complex concentration was set at 4.5 μM. (Right) The total volume of shelterin condensates settled per micron squared area on the coverslip in the absence or presence of RAP1. The center and edges of the box represent the median with the first and third quartile (n = 20 with two technical replicates). The p-values were calculated from a two-tailed t-test. C. Example images show phase separation of 4.5 μM 5comp in the presence and absence of nucleosomes wrapped with telomeric or nontelomeric DNA. D. Volume of droplets settled per micron squared area and partition coefficient of nucleosomes into 5comp droplets. The center and edges of the box represent the median with the first and third quartiles (n = 20 droplets with two technical replicates). See also Figure S6.
Figure 7.Shelterin droplets selectively recruit telomere-associated factors.
A. 5comp droplets are settled onto PEG surfaces decorated with 8ds3ss. (PEG: polyethylene glycol, SA: streptavidin; not to scale). B. 100 nM Cy3-TERRA, 15 nM Alexa488-MRN complex, or 100 nM GFP-RPA are introduced to 7.6 μM Cy5-5comp droplets. TERRA partitions strongly into the droplets, while MRN and GFP-RPA are initially excluded from the droplets and uniformly distributed after 60 min incubation. C. Partitioning of 100 nM Cy3-TERRA, 15 nM Alexa488-MRN, or 100 nM GFP-RPA into 7.6 μM 5comp droplets over time (mean ± SD, n = 3 droplets per condition). D. Partition coefficients of DDR proteins and telomere-associated factors in 7.6 μM 5comp droplets after 60 min incubation. The center and edges of the box represent the median with the first and third quartile (n = 10 droplets per condition). E. (Left) Multicomponent phase diagram of telomere condensation with balanced stoichiometry. No condensation results at low shelterin concentrations and/or short telomeres. (Top) Telomere condensation, formed by both heterotypic (dark dashes) and homotypic (light dashes) interactions, selectively recruit telomere-associated factors while acting as a diffusion barrier against other components that target telomeric DNA, like RPA. The enrichment of shelterin, and thus POT1, outcompetes RPA binding to ssTEL. (Bottom) Shortened telomere scaffold cannot recruit enough shelterin to form a condensate, which could fail to protect the ssTEL overhang against RPA binding. See also Figure S7 and Movie S5.
KEY RESOURCES TABLE
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
|
| ||
| Rabbit anti-TRF2 | Novus Biologicals | Cat#NB110-57130 |
| Mouse anti-Histone H3 | Abcam | Cat#Ab10799 |
| Anti-Mouse IgG, Peroxidase Conjugated, Goat | Jackson ImmunoResearch | Cat#115-035-062 |
| Anti-Rabbit IgG, Peroxidase Conjugated, Goat | Jackson ImmunoResearch | Cat#111-035-144 |
| Rabbit anti-53BP1 | Novus Biologicals | Cat#NB100-305 |
| Goat anti-Rabbit IgG, AlexaFluor 647 conjugated | Thermo Fisher Scientific | Cat#A-21245 |
| Anti-FLAG M2, mouse | Sigma-Aldrich | Cat#F1804 |
|
| ||
| XL1Blue | MacroLab, University of California Berkeley | N/A |
| Rosetta | MacroLab, University of California Berkeley | N/A |
| DH10Bac | MacroLab, University of California Berkeley | N/A |
| BL21(DE3)pLysS | Sigma-Aldrich | Cat#69451 |
|
| ||
|
| ||
| Fugene HD Transfection Reagent | Promega | Cat#E2311 |
| TEV protease | MacroLab, University of California Berkeley | Addgene Cat#8827 |
| Streptavidin | ThermoFisher Scientific | Cat#434301 |
| LD655-CoA | Lumidyne Technologies | Custom synthesis |
| LD555-CoA | Lumidyne Technologies | Custom synthesis |
| Bradford Reagent | Bio-Rad | Cat#500-0006 |
| Benzonase nuclease | Sigma Aldrich | Cat#E1014-25KU |
| Blocking reagent | Millipore Sigma | Cat#11096176001 |
| Fetal Bovine Serum, Premium, Heat-Inactivated | Atlanta Biologicals | Cat#S11150H |
| Fibronectin Bovine Plasma | Millipore Sigma | Cat#F1141 |
| FITC-TelC, C-rich telomere probe, FITC labeled | PNA bio | Cat#F1009 |
| Formamide (Deionized) | Thermo Fisher | Cat#AM9342 |
| GIBCO DMEM, High Glucose, Pyruvate | Thermo Fisher Scientific | Cat#11995065 |
| GIBCO DPBS, no calcium, no magnesium | Thermo Fisher Scientific | Cat#14190144 |
| GIBCO Opti-MEM Reduced Serum Medium | Thermo Fisher Scientific | Cat#31985062 |
| GIBCO Penicillin-Streptomycin (10,000 U/mL) | Thermo Fisher Scientific | Cat#15140122 |
| Hoechst 33342, 10mg/mL | Thermo Fisher Scientific | Cat#H3570 |
| In-Fusion HD Cloning Plus | Takara Bio | Cat#638910 |
| Lenti-X Concentrator | Takara Bio | Cat#631231 |
| Normal Goat Serum Blocking Solution | Vector Laboratories | Cat#S-1000-20 |
| NuPAGE™ LDS Sample Buffer (4X) | Thermo Fisher | Cat#NP0007 |
| Oligofectamine | Thermo Fisher | Cat#12252011 |
| Paraformaldehyde (16%) | Electron Microscopy Science | Cat#15710 |
| Phusion® High-Fidelity DNA Polymerase | New England Biolabs | Cat#M0530L |
| Pierce RIPA buffer | BCA | Cat#89901 |
| Protease Inhibitor tablets (EDTA-free) | Sigma | Cat#4693132001 |
| Puromycin dihydrochloride from Streptomyces alboniger | Sigma | Cat#P7255 |
| SuperSignal West Pico PLUS Chemiluminescent Substrate | Thermo Fisher | Cat#34577 |
| Transit293 Transfection Reagent | Mirus | Cat#MIR 2700 |
| TRIS-buffered saline (TBS, 10X) pH 7.4 | Fisher Scientific | Cat#AAJ62938K2 |
| Triton X-100 | Promega | Cat#H5142 |
| Tween-20 | Thermo Fisher | Cat#BP337-100 |
| Vectashield Plus Antifade Mounting Medium with DAPI | Vectashield | Cat#H-2000-10 |
| ESF 921 Insect Cell Culture Medium | Expression Systems | Cat#NC903611 |
| Antibiotic-antimycotic | Thermo Fisher Scientific | Cat#15240062 |
| Fetal Bovine Serum | Corning | Cat#35-010-CV |
| ZymoPURE miniprep kit | Zymo Research | Cat#D4210 |
| Alexa Fluor 488 antibody labeling kit | Thermo Fisher Scientific | Cat#A20181 |
| Atto488 maleimide dye | Sigma-Aldrich | Cat#28562 |
| SYBR-Safe | Thermo Fisher Scientific | Cat#S33102 |
| Genejet PCR purification kit | Thermo Fisher Scientific | Cat#K0701 |
| Cy3 Label IT kit | Mirus Bio | Cat#MIR 3600 |
| Biotin-BSA | Sigma-Aldrich | Cat#9048-46-8 |
| Streptavidin | Thermo Fisher Scientific | Cat#434301 |
|
| ||
|
| ||
| SF9-ESF S Frugiperda | Berkeley Cell Culture Facility | RRID:CVCL_0549 |
| Human: U-2 OS | ATCC | ATCC® HTB-96™ |
| Human: Lenti-X™ 293T | Takara Bio | Cat#632180 |
| Human: hTERT-RPE1 (p53−/−, Rb−/−) | Titia de Lange, Rockefeller Univ. | N/A |
| Human: HeLa RMCE GFP-TRF1 | Huaiying Zhang, Carnegie Mellon Univ. | N/A |
|
| ||
|
| ||
| See | ||
| siRNA targeting human TRF2 (#2 sequence from | IDT | N/A |
| siRNA targeting human TRF2 (#4 sequence from | IDT | N/A |
| siRNA targeting human TRF2 (sequence from | IDT | N/A |
| Scrambled RNAi (sequence from | IDT | N/A |
| Thermo Fisher Scientific | Cat#AM4621 | |
|
| ||
| CDS: iLID |
| N/A |
| CDS: TRF1 (NCBI Reference sequence: NM_003218.3) | IDT gBlock with codon optimization | N/A |
| CDS: TRF2 (NCBI Reference Sequence: NM_005652.5) | IDT gBlock with codon optimization | N/A |
| Plasmid: FM5-iLId-miRFP-TRF1 | This paper | N/A |
| Plasmid: FM5-GFP-TRF2 | This paper | N/A |
| Plasmid: FM5-miRFP-TRF1 | This paper | N/A |
| Plasmid: FM5-miRFP-TRF2 | This paper | N/A |
| Plasmid: FM5-sspB-mCherry |
| N/A |
| Plasmid: FM5-sspB-mCherry-TRF1A75P | This paper | N/A |
| Plasmid: FM5-sspB-mCherry-TRF2 | This paper | N/A |
| Plasmid: FM5-sspB-mCherry-TRF2Acidic | This paper | N/A |
| Plasmid: FM5-sspB-mCherry-TRF2ΔB | This paper | N/A |
| Plasmid: FM5-TRF1-mCherry-sspB | This paper | N/A |
| Plasmid: pCMV-dR8.91 | Toettcher Lab, Princeton University | N/A |
| Plasmid: pMD2.G | Toettcher Lab, Princeton University | N/A |
| Plasmid: pHR-FUSN-mCherry-sspB |
| N/A |
| Plasmid: pHR-FUSN-miRFP-TRF1 | Shunsuke Shimobayashi (Brangwynne Lab, Princeton University) | N/A |
| Plasmid: pHR-NLS-iLID-EGFP-FTH1 |
| N/A |
| Plasmid: PSP |
| N/A |
| Plasmid: VSVG |
| N/A |
| Plasmid: EGFP-pBAD | Davidson Lab, Florida State University | Addgene Cat#54762 |
| Plasmid: pet29b-SFP-His | Worthington & Burkart, 2006 | Addgene Cat#75015 |
| Plasmid: pET-H2A |
| N/A |
| Plasmid: pET-H2B |
| N/A |
| Plasmid: pET-H3 |
| N/A |
| Plasmid: pET-H4 |
| N/A |
| Plasmid: pGEM-3z/601 |
| Addgene Cat#26656 |
| Plasmid: pOmnibac zz TEV YBBR TRF1 | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1ΔA | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1ΔHinge | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1ΔIDR | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1Hinge | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1HingeMyb | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1GSTHingeMyb | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1Basic | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2 | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2ΔB | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2ΔHinge | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2ΔIDR | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2Hinge | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2HingeMyb | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2GSTHingeMyb | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2GSTSub | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2 ΔTRFH | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2Acidic | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF1A74D | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR TRF2Y102F | This paper | N/A |
| Plasmid: pOmnibac zz TEV YBBR POT1 | This paper | N/A |
| Plasmid: pBig1a zz TEV YBBR TPP1 MBP TEV TIN2 | This paper | N/A |
| Plasmid: pBig2ab zz TEV YBBR POT1 ZZ TEV TPP1 MBP TEV TIN2 ZZ TEV TRF1 (4comp1) | This paper | N/A |
| Plasmid: pBig1a zz TEV YBBR POT1 MBP TEV TPP1 MBP TEV TIN2 ZZ TEV TRF2 (4comp2) | This paper | N/A |
| Plasmid: pBig1a zz TEV YBBR RAP1 ZZ TEV TRF2 | This paper | N/A |
| Plasmid: pLIB MBP TEV YBBR RAP1 | This paper | N/A |
| Plasmid: pRST5-Spinach-39xTelG | This paper | N/A |
|
| ||
| Fiji (ImageJ 1.52p) | NIH |
|
| 3D objects Counter (Fiji) |
| |
| 3D Multicoloc in 3D ImageJ suite (Fiji) |
| |
| GraphPad PRISM 9.1.0 | GraphPad |
|
| MATLAB 2019b | MathWorks |
|
| Python 3.7.10 | Python Software Foundation |
|
| Origin 8.5.0 SR1 | OriginLab Corporation |
|
|
| ||
| IgG Sepharose beads | GE Healthcare | Cat#17096902 |
| HisPur Ni-NTA beads | Thermo Fisher Scientific | Cat#88221 |
| Amylose beads | New England BioLabs | Cat# E8021S |
| Superdex 200 Increase 10/300 GL | Cytiva | Cat#28-9909-44 |
| Superdex 200 10/300 GL | Cytiva | Cat#17517501 |
| NuPAGE 4-12% Bis-Tris gel | Thermo Fisher Scientific | Cat#NP0322BOX |
| PEG-Biotin cover slips | MicroSurfaces, Inc | Cat# Bio_02 |
| Trans-Blot Turbo Mini 0.2 um PVDF transfer pack | Bio-Rad | Cat#1704156 |
| 40kDa Zeba spin desalting column | Thermo Fisher Scientific | Cat#87766 |
| HiTrap SP HP | GE Life Sciences | Cat#95056-076 |
| HiTrap DEAE-FF | Cytiva | Cat#17515401 |
| Amersham Typhoon | GE Life Sciences | Cat#29238583 |